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ABSTRACT
Among all the dosages, oral is the best route of administration for its advantages but due to flow of its demerits like poor bioavailability due to first pass 
metabolism and unpredictable nature of gastrointestinal absorption. Moreover, oral route is cost prohibitive and inconvenient. Transdermal patches 
are medicated adhesive patches when it was placed on the skin layer it will deliver the drug into the blood stream through skin layer. To overcome the 
side effects caused by the oral route, drugs given through transdermal are preferred as transdermal patch. By employing sustained release polymers, 
transdermal patches can be prepared using solvent casting method. Drug excipients compatibility studies are very important to determine whether 
the excipients are suitable for that drug or not. These compatibility studies are very important to maintain the stability of dosage form. Evaluation 
studies are very important to determine the accuracy of dosage form at the same time therapeutic action also. Some of the parameters such as 
weight variation, physical appearance, drug content, moisture uptake, folding, endurance, swelling study and physical appearance, in vitro dissolution 
studies, ex vivo studies, and in vivo studies were evaluated.
Keywords: Transdermal, Reservoir, Epidermis, Bioavailability, Skin Permeation.
INTRODUCTION
Transdermal drug delivery system (TDDS) also known as “patches” 
(non-invasive delivery) is dosage form designed to deliver a medication 
across a patient skin [1,2]. Skin is the largest and most accessible organ 
of human body with the help of skin layers drug reaches into the blood 
stream given as sustained release, controlled release, or extended-
release formulation and shown in Fig. 1 [1].
Transdermal delivery systems are specifically designed to obtain 
systemic blood levels and have been used in the US since the 1950s. The 
first transdermal system, transdermal SCOP was approved by FDA in 
1979 for the prevention of nausea and vomiting associated with travel. 
Most transdermal patches are designed to release the active ingredient 
from several hours to days following application to the skin. This is 
especially advantageous for prophylactic therapy in chronic conditions. 
The evidence of percutaneous drug absorption may be found through 
measurable blood levels of the drug, detectable excretion of the drug, 
and its metabolites in the urine and through the clinical response of the 
patient to the administered drug therapy [3].
Transdermal permeation or percutaneous absorption can be defined as 
the passage of a substance, such as a drug, from the outside of the skin 
through its various layers into the blood stream [2].
Certainly, each dosage form has its unique place in medicine, but 
some attributes of the transdermal delivery system provide distinct 
advantages over traditional methods. In the development of the 
transdermal delivery system [4], a series of interrelated elements must 
be taken into consideration. These elements can be classified into five 
basic areas:





The transport of drugs through the skin is complex since many factors 
influence their permeation to simplify the situation somewhat, one 
should consider the following [4]:
•	 Skin structure and its properties.
•	 The penetrating molecule.
•	 Physical-chemical relationship to the skin.
•	 The delivery platform.
•	 The platform or delivery system carrying the penetrant.
•	 The combination of skin.
•	 Penetrant.
Advantages
•	 Avoidance of first-pass metabolism.
•	 Avoidance of gastrointestinal compatibility.
•	 Minimizing undesirable side effects.
•	 Avoiding the fluctuation in drug levels.
•	 Maintain plasma concentration of potent drugs [5-9].
Limitations
•	 Transdermal patches cannot deliver ionic drugs.
•	 Transdermal patches cannot achieve high drug levels in blood/
plasma.
•	 Transdermal patches cannot deliver drugs in a pulsatile fashion.
•	 It cannot develop for drugs of large molecular size [6-10].
The process of drug absorption through the percutaneous route 
is shown in Fig. 2 and different types of transdermal patches are 
shown [14,15] in Fig. 3.
COMPONENTS OF TRANSDERMAL PATCHES
Some of the components used for transdermal patch are [16-21]:
•	 Liner: It is removed before using it gives protection to patch during 
storage. For example, polyester film.
•	 Drug: It is directly in contact with release layer. For example, nicotine, 
methotrexate, and estrogen
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3. Membrane matrix hybrid.
4. Microreservoir type.
5. Drug in adhesive.
•	 Single layer drug in adhesive.
•	 Multilayer drug in adhesive.
6. Miscellaneous: Hybrid matrix type, vapor patch, etc.
Matrix type
Matrix type of transdermal patch was designed in the year 1990s. Here, 
the patch is very slim and less visible when sticked on the skin. In this 
type, the film controls release of medication from the patch. In this 
method, the drug and polymer dissolved in solvent (soluble) or insoluble 
drug homogeneously dispersed in hydrophilic or lipophilic polymer. To 
the above, add required quantity of plasticizer and permeation enhancer. 
Medicated polymer formed is then molded into the ring with defined 
surface area and controlled thickness over the mercury on horizontal 
surface followed by solvent evaporation at an elevated temperature. Thus, 
film formed is separated from the ring and mounted onto the occlusive 
base plate in a compartment fabricated from a drug impermeable backing. 
Then, an adhesive polymer is then spread along the circumference of the 
film. The adhesive layer and backing are integrated into one layer, are 
shown in Fig. 4 [17]. A few examples of matrix type transdermal patches 
are Nitro-glycerin transdermal  patch-Nitro Dur®.
Advantages
1. Avoidance of first-pass effect.
2. Avoid gastrointestinal track difficulties which are caused by enzymes 
and food interactions.
3. Stable and controlled blood level.
4. Ease of termination of drug action if necessary.
5. Poor oral bioavailability.
6. Narrow therapeutic window.
7. No interference with gastric and intestinal fluids.
8. Less chances for overdose.
Disadvantages
1. The transdermal delivery is unsuitable when the dose is high.
2. Drug is skin sensitizing, skin irritating and it gets metabolized in 
skin.
3. Drug undergoes protein binding in skin.
4. Drug is highly lipophilic or hydrophilic.
Reservoir type
It is different from single layer drug in adhesive and multilayer drug 
in adhesive systems. It is having separate drug layer. In this, the drug 
reservoir layer is a liquid compartment which is consisting of drug 
solution or the suspension where the drug particle is suspended in 
silicon fluid gives paste such as suspension/gel/clear solution in ethanol, 
which is separated by the adhesive layer. The rate controlling membrane 
is prepared by solvent evaporation or compression method. This patch 
is also consisting of backing layer, as shown in Fig. 5 [17]. Advantage of 
this type is it follows true zero order release to achieve a constant serum 
drug level, for example: Duragesic®, Estraderm®, and Androderm®.
Membrane matrix hybrid
It is the modified form of reservoir matrix in which the liquid form of 
drug reservoir is replaced with solid matrix polymer (polyisobutylene), 
example for this type is Catapress®.
Micro reservoir type
In this type, the drug is suspended in an aqueous solution of water 
miscible drug solubilizer poly ethylene glycol (PEG) or drug suspension 
is homogenously dispersed by a high shear mechanical force in 
lipophilic polymer, forming 1000s of unleachable microscopic drug 
particles. The dispersion is quickly stabilized by immediately cross-
linking the polymer chain, in situ produces a medicated polymeric disc 
of specific area a thickness, is shown in Fig. 6 [17], the example for this 
type is Nitrodisc®.
•	 Adhesive: It helps in adhering the components of patch with each 
other and helps in adhering the patch to skin patch. For example, 
acrylates, polyisobutylene, silicones, etc.
•	 Membrane: It helps in release of drug from reservoir and multilayer 
patches.
•	 Backing: It gives protection to the patch from the atmosphere. For 
example, cellulose derivatives and polyvinyl alcohol.
TYPES OF TRANSDERMAL PATCH
Transdermal patches were categorized into four main types [22-25]:
1. Matrix type.
2. Reservoir type.
Fig. 1: Transdermal patch application on the skin
Fig. 2: Schematic representation of percutaneous absorption
Fig. 3: Different types of transdermal patches
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Drug in adhesive
In this, drug and excipient are incorporated in organic solvent-based 
pressure sensitive adhesives solutions and mixed. Then, cast as a thin 
film and dried to evaporate the solvent, then the dried adhesive matrix 
film is sandwiched between release liner and backing layer. Some of the 
examples are Climara®, Nicotrol®, and Deponit®.
Single-layer drug-in-adhesive
The adhesive layer consisting of drug. In this type of patch, adhesive 
layer not only serves to adhere to various layers of patch together and 
with entire patch to the skin but it is also responsible for drug release 
from the patch. The adhesive layer is surrounded by temporary layer 
and backing is shown in Fig. 7.
Multilayer drug-in-adhesive
It is similar as that of single-layer drug-in-adhesive. Here, both the adhesive 
layers are responsible for releasing the drug. However, the multilayer 
patch is somewhat different that it adds another layer of drug-in-adhesive 
and it was separated by a membrane in some cases. This patch is having 
temporary liner layer and a permanent backing, is shown in Fig. 8.
BASIC COMPONENTS OF TRANSDERMAL PATCHES
1. Active pharmaceutical ingredient (API).
2. Polymer matrix/drug reservoir.
3. Permeation enhancers.
4. Pressure sensitive adhesive.
5. Backing laminates.
6. Release liner.
7. Other excipients such as plasticizers and solvents.
API
API selection for the preparation of transdermal patches should meet 
the following conditions [26-29]:
•	 Must no induce cutaneous irritant and allergic response and should 
not cause adverse effects to non-target tissues.
Polymer matrix
Polymer selection criteria for the preparation of transdermal patches 
are as follows [30-33]:
•	 Provide consistent and effective delivery of drug.
•	 Should not deteriorate throughout the shelf life of the drug.
•	 Stable, easily manufactured and fabricated into the desired 
product.
•	 If degraded must be non-toxic and non-antagonistic to host.
•	 Biocompatible and chemical compatibility with drug and others.
Polymers are classified based on the nature:
•	 Natural polymer: Cellulose derivatives, gelatin, shellac, waxes, gums, 
etc.,
•	 Synthetic elastomers: Polybutadiene, hydrin rubber, butyl rubber, 
etc.,
•	 Synthetic polymer: Poly vinyl acetate (PVA), poly vinyl cellulose 
(PVC), poly ethylene (PE) polypropylene, etc.
Few examples of mostly used polymers for transdermal patches are 
for matrix former (PEG, Eudragit, Ethylene cellulose (EC), poly vinyl 
pyrrolidine (PVP), and hydroxy propyl methyl cellulose (HPMC)) 
and rate controlling membrane (Ethylene vinyl acetate (EVA), silicon 
rubber, and polymethane).
Pressure sensitive adhesive
These selections are based on patch design and drug formulation (helps 
in maintaining an intimate contact between transdermal patch and the 
skin surface) [34,35].
•	 Matrix system: Peripheral adhesives-incidental contact between 
adhesives and the drug and penetration enhancers.
•	 Reservoir system: Face adhesive diffusing drug must not affect the 
adhesive.
•	 Drug in adhesive matrix system: Rate at which the drug and 
permeation enhancers will diffuse through the adhesive.
Pressure sensitive adhesive should be selected based on the following 
criteria:
•	 Adhere with Not more than (NMT) applied finger pressure.
•	 Permanently tachy and exert a strong holding face.
•	 Be removable from the smooth surface without leaving a residue.
•	 Physicochemical and biologically compatible and should not alter 
drug release.
Mostly used pressure sensitive adhesives are polysiloxane, polyacrylate, 
polyisobutylene, and silicon.
Fig. 4: Matrix type drug in adhesive
Fig. 5: Reservoir type drug in adhesive
Fig. 6: Micro reservoir type drug in adhesive
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done to know the performance, stability, shelf life, and reproducibility 
of the drug, under environmental conditions. The following are the 
some of the classes of evaluation studies carried out for evaluating the 
transdermal patches:
1. Physicochemical evaluation
2. In vitro evaluation
3. In vivo evaluation
Physicochemical evaluation
Physicochemical evaluation is done by considering the following 
parameters [44-46]:
•	 Thickness
•	 Uniformity of weight
•	 Drug content determination







The thickness of the transdermal patches was measured by the 
microscope, screw gauge, and dial gauge at different points of the film.
Uniformity of weight
It is also called weight variation. It can be studied individually by 
weighing 10 randomly selected patches. Then, the average weight of 
the patches was taken. The individual weight should not deviate from 
the average weight.
Drug content determination
Accurately weigh the film and dissolve it in the 100 mL of suitable solvent 
in which the drug is soluble. Then, this solution is shaken continuously 
for 24 h in the shaker incubator. Then, this solution can solicit. After the 
fornication and filtration, the drug in the solution is estimated by the 
spectroscopy by making appropriate dilutions.
Drug content uniformity test
Ten patches were selected randomly, and the content is determined 
for patches individually. The results should be like this, out of these 
10 patches, 9 should be in the range between 85% and 115% of the 
specified value and remaining 1 patch should be in the range of 75–
125%, then, it is considered as the patches have passed the test. If 
three patches have the content in the range of 75–125%, then other 20 
patches should be taken and those should be present in the range of 
85–125% to pass the test.
Moisture content
Prepared films were taken and then weigh them individually and then 
keep them in the desiccator which is containing calcium chloride. 
After completion of 24 h at the room temperature, all the films should 
again weigh. Using the formula given in Eq. 1, the percentage moisture 
content is determined.
        












Weigh the films first and then these films were kept in the desiccator at 
the room temperature for 24 h. The relative humidity of 84% is exposed 
to those patches using the saturated solution of potassium chloride 
in the desiccator until the constant weight is achieved. The moisture 
uptake is determined by the formula given in Eq. 2.
Permeation enhancers
These play a major role in preparation of transdermal patches, thereby 
enhancing the permeation of drug through the skin can be by the 
following functions:
•	 Increase permeability of stratum corneum to attain higher 
therapeutic levels of the drug.
•	 These interact with structural components of stratum corneum, that 
is, protein/lipids.
•	 They alter the protein and lipid packaging of stratum corneum, 
thus chemically modify the barrier functions leading to increased 
permeability.
•	 Solvates: Increase permeations by swelling the polar pathway and/
or fluidizing lipids. For example: Water, ethanol, methanol, propylene 
glycol, pyrrolidone, isopropyl myristate, and azone
•	 Surfactants: Enhance the polar pathway transport for hydrophilic drugs. 
For example, SLS, dimethyl sulfoxide, sodium deoxycholate, etc. [36-38].
Backing laminates
Backing membranes are flexible and they provide a good bond to the 
drug reservoir, prevent drug from leaving the dosage form through 
the other side of the transdermal patch, and accept printing. It is 
impermeable. Substance that protects the product during use on 
the skin, for example, metallic plastic laminate, plastic backing with 
absorbent pad and occlusive base plate, adhesive foam pad with 
occlusive base plate, etc. [39-41].
Release liner
•	 Primary packing material for delivering drug.
•	 Protective liner that is remover and discharges immediately before 
the applying the patch to skin.
•	 As the liner is in intimate contact with the delivery system, it 
should be chemically inert, permeation to the drug, and penetration 
enhancers and water.
•	 It is composed of a base layer which may be non-occlusive (paper 
fabric) or occlusive (polyethylene and PVC) and release coating layer 
made up of silicon or Teflon.
•	 For example: Polyester foils and metalized laminates [42].
Other excipients such as plasticizers and solvents
•	 Various solvents: Chloroform, methanol, acetone, isopropanol, and 
dichloromethane are used to prepare drug reservoir.
•	 Plasticizers: Dibutyl phthalate, triethyl citrate, PEG, and Propylene 
glycol added to provide plasticity to TD patches [43].
EVALUATION OF TRANSDERMAL PATCHES
Transdermal patches were developed to improve the efficacy of the 
drug and to enhance the patient comfort by delivering the small amount 
of the drug only at predetermined rate. Evaluation tests should be 
Fig. 7: Single-layer drug in adhesive
Fig. 8: Multilayer drug in adhesive
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The transdermal patch should be smooth and should not be constricted 
with the time. Hence, this study was performed. For the determination of 
the flatness, one patch is cut down from the center and the two from each 
side of the patch. The length can be determined by the percent constriction 
given in Eq. 3. About 0% constriction is equivalent to 1005 flatness.













Where: I1 = Initial length of the strip and I2 = Final length of the strip.
Folding endurance
Evaluation of folding endurance involves determining folding capacity of 
films after that subject them to the extreme conditions of folding. Folding 
endurance can be determined by repeatedly folding the film at the same 
place without breaking. That is the folding endurance value of that patch.
In vitro release studies
The amount of drug available for the absorption into the blood is depends 
on the release of the drug from the polymeric transdermal film. The 
drug that reaches the surface of the skin is passed to usual permeation 
studies, which were performed by attaching the transdermal patch to the 
rat skin or to the synthetic membrane which is present in between the 
receptor and donor in vertical diffusion cells. The transdermal system is 
applied to hydrophilic side of the membrane and the lipophilic side is in 
contact with the receptor fluid. The receiver compartment is maintained 
at specific temperature usually 32°C and stirred continuously. The 
samples were withdrawn at equal time intervals and an equal amount 
of buffer is replaced at each time. The samples were diluted, and the 
absorbance is determined using UV spectrophotometer. The amount of 
the drug permeated per square centimeter at each interval is calculated. 
Drug release is depending on design of the system, patch size, surface 
area of the skin, thickness of the skin and temperature, etc. [47,48].
In vivo studies
In these evaluation studies, the drug performance can be depicted truly. 
In this study, the TDDS can be carried out using.
•	 Animal models.
•	 Human volunteers or human models.
Animal models
Animal studies can be preferred mainly by the time and the resources 
which were required to carry out the human studies. Most common 
animal species used for the evaluating the transdermal patches on 
mouse. Hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea 
pig, etc., various experiments conducted on these animals lead us to the 
conclusion that the conclusions the hair less animals were preferred 
over the hairy animals in both in vivo and in vitro experiments. The 
most reliable model for performing this experiment is rhesus monkey.
Table 2: Examples of marketed transdermal drug  
delivery system
S. No. Therapeutic 
ingredient
TDDS Design [65]




2. Estradiol Estraderm 
(Novartis)
Four-layer patch
3. Estradiol Vivelle (Novartis) Three-layer system
4. Estradiol Climara 
(Novartis)
Three-layer system
5. Fentanyl Duragesic 
(Janssen)
Four-layer patch
6. Nicotine Prosstep 
(Lederie)
Multilayer round patch
7. Testosterone Testoderm (Alza) Three-layer system
8. Nicotine Habitrol (Novartis 
Consumer)
Multilayer round patch










Table 3: Research works on transdermal drug delivery systems
S. No. Name of the drug Method Uses
1. Topiramate [51] Solvent casting 
technique
Epilepsy, Migraine
2. Simvastatin [52] Solvent casting 
technique
Hypercholesterolemia
3. Repaglinide [53] Solvent casting 
technique
Diabetes mellitus










6. Glipizide [56] Solvent evaporation 
technique
Diabetes mellitus
7. Carvedilol [57] Solvent evaporation 
technique
Hypertension
8. Propranolol [58] Solvent evaporation 
technique
Hypertension
9. Ketoprofen [59] Solvent evaporation 
technique
Osteoarthritis








12. Ibuprofen [62] Gel preparation NSAID








15. Doxophylline [64] Solvent evaporation 
method
Antiasthmatic 
Table 1: Marketed products of transdermal patches
S. No. Product Active drug Type of patch Purpose
1. Estraderm Estradiol Membrane Postmenstrual 
syndrome
2. Alora [12] Estradiol Membrane Postmenstrual 
syndrome
3. Duragesic [11] Fentanyl Reservoir Pain relief patch
4. Matrifen [12] Fentanyl Reservoir Pain relief patch
5. Transderm  
Scop [11]
Scopolamine Matrix Motion sickness
6. Deponit [11] Nitroglycerine Drug in 
adhesive
Angina pectoris
7. Lidoderm [11] Lidocaine Drug in 
adhesive
Anesthetic
8. Testoderm  
TTS [11]
Testosterone Reservoir Hypogonadism 
in males
9. Fematrix [11] Estrogen Matrix Postmenstrual 
syndrome
10. Nitro-Dur [11] Nitroglycerine Matrix Angina pectoris
11. Nitrodisc [12] Nitroglycerine Matrix Angina pectoris
12. Minitran [13] Nitroglycerine Matrix Angina pectoris
13. Nitro-Dur [13] Nitroglycerine Matrix Angina pectoris
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Human models
It is the final stage for the development of the transdermal device 
involving the collection of the pharmacokinetic and pharmacodynamic 
data from the human volunteers by the application of the patch. The 
clinical trials were conducted by various parameters such as efficacy, 
risk involved, side effects, and patient compliance. Phase 1 clinical trials 
are conducted to determine the safety of the volunteers and the Phase 
2 clinical trials were mainly to determine the short-term safety and 
the effectiveness in the patient. Phase 3 trails indicate the safety and 
effectiveness in the large number of patients. Phase 4 trials at the post 
marketing surveillance are done for the marketed patches to detect the 
adverse drug reactions. These are the best to assess the performance of 
the drug [49,50].
Few of the marketed products of transdermal patch in different forms 
with purposes and designs were given in Tables 1 and 2. The recent 
research works carried out on transdermal patches were given in 
Table 3.
Few examples for improved drug delivery over other routes such 
as insulin delivery [66], improve penetration [67,68], improve 
bioavailability when compared with oral route of administration [69].
CONCLUSION
Improvement in the TDDS is a successful story of the pharmaceutical 
endeavor. Several transdermal patches are present in the market, 
which were a valid proof that the transdermal systems were feasible, 
safe, and effective with maximum patient compliance. Transdermal 
drug delivery of tacrine was developed mainly to overcome first-
pass metabolism and to reduce the frequency when compared to oral 
route of administration. Oral route of administration is having many 
disadvantages like less bioavailability, high dose is needed or frequent 
dosing, which may be cost prohibitive and also not convenient to some 
patients. Using Eudragit polymer, transdermal patches can be prepared 
by solvent casting method. In general, matrix type of transdermal 
patches was manufactured using polymers. All these transdermal 
patches were evaluated for various parameters such as physical 
appearance, thickness, weight variation, drug content, moisture uptake, 
moisture content, and swelling studies.
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